Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

The RESPONDER trial: a feasibility study of an early intervention model deploying community first responders to administer intranasal naloxone in suspected opioid overdoses in Skåne, Sweden.

Created on 29 Jun 2026

Authors

Julia Rehn, Cecilia Andréll, Josephine Hansson, Katja Troberg, Pernilla Isendahl, Martin Bråbäck, Leif Svensson, Fredrik Byrsell, Andreas Claesson, Anders Håkansson

Published in

BMJ open. Volume 16. Issue 6. Pages e115692. Jun 28, 2026. Epub Jun 28, 2026.

Abstract

Opioid use continues to cause harm and fatalities worldwide, despite ongoing preventive efforts. Early administration of the antidote naloxone can reverse potentially fatal opioid overdoses. Naloxone distribution programmes have increased survival across regions; however, additional efforts are needed to reduce opioid overdose mortality. One approach is to expand naloxone availability within communities.
The feasibility trial RESPONDER (REgion Skåne Preventing Overdose deaths through Naloxone Distribution with Emergency Runners) introduces a unique smartphone alerting system with community first responders (CFRs) dispatched to suspected opioid overdoses, in addition to the dispatch of regular emergency medical services (EMS). The aim is to investigate if trained CFRs can successfully recognise and reverse overdoses caused by opioids, prior to EMS arrival. The CFRs will be equipped with nasal naloxone and introduced to a novel naloxone algorithm during a study-specific course prior to participation. The course will offer practical training in basic life support and first aid, and it will also assess competence in the low-arousal approach, as well as the legal and ethical aspects of being a CFR.Main outcomes of the trial are feasibility, acceptability and safety. The trial will be performed in the region of Skåne, Sweden, between 1 September 2025 and 31 August 2027, with every CFR followed for up to 12 months.
The trial has been approved by the Swedish Ethical Review Authority (file number 2024-05887-01). Written informed consent is required from participating CFRs. This is also required of overdose survivors to allow the collection of clinical data from hospital records.Information regarding the project and recruitment will be disseminated via social media, news media, through the healthcare region's communication channels and within public transportation hubs. Outcomes and analyses will be submitted to peer-reviewed journals.
NCT07079241.

PMID:
42365998
Bibliographic data and abstract were imported from PubMed on 29 Jun 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 3
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement